NASDAQ · Biotechnology

Coeptis Therapeutics Holdings, Inc. (COEP) Stock

$10.99 -8.57% NASDAQ: COEP Healthcare

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

Valuation

MetricValue
Price$10.99
Market Cap$38.62M
P/E Ratio-4.45
P/B Ratio3.18
P/S Ratio27.31
EPS (TTM)$0.00
52-Week High$21.41
52-Week Low$6.80
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-83.85%
ROA-60.00%
ROCE-71.80%
Gross Margin87.23%
Operating Margin-912.42%
Net Margin-839.69%
Debt/Equity0.02
Current Ratio3.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-14.0M$-34.0M$-21.0M$-10.0M$-13.0M
Net Profit$-13.0M$-38.0M$-21.0M$-11.0M$-12.0M
EPS$-13.16$-2.87$-0.83$-5.65$-2.81
Op Margin-18727.9%———-956.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$7.0M$8.0M$8.0M$9.0M$20.0M
Total Liabilities$4.0M$3.0M$4.0M$5.0M$2.0M
Cash$2.0M$4.0M$1.0M$1.0M$6.0M
Borrowings$4.0M$2.0M$1.0M$1.0M$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-4.0M$-7.0M$-7.0M$-9.0M
Investing Cash Flow$-3.0M$0$0$0$0
Financing Cash Flow$0$5.0M$0$1.0M$0
Net Cash Flow$2.0M$2.0M$-2.0M$-1.0M$5.0M
Free Cash Flow$-6.0M$-4.0M$-7.0M$-7.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-3.10
FCF Yield-20.71%
Quick Ratio3.25
Interest Coverage-22.39
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics Holdings, Inc. is led by CEO David Mehalick, employs 5 people, headquartered in US, publicly traded since 2020.

Coeptis Therapeutics Holdings, Inc. (COEP) stock trades at $10.99 with a market capitalization of $38.62M. The stock is valued at a price-to-earnings (P/E) ratio of -4.45, price-to-book of 3.18, price-to-sales of 27.31. Over the past 52 weeks the stock has ranged between $6.80 and $21.41, and currently trades 48.7% below its 52-week high.

On profitability, Coeptis Therapeutics Holdings, Inc. generates a return on equity (ROE) of -83.85%, return on capital employed of -71.80%, an operating margin of -912.42%, a net profit margin of -839.69%.

Official website: coeptistx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides